Gilead’s Zydelig, formerly known as idelalisib, has been approved. The FDA greenlighted the drug for three cancers: chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.

Zydelig is a first-in-class phosphoinositide 3-kinase delta inhibitor. The drug snared breakthrough status for the CLL indication. Despite the first-in-class status, the drug already has competition, including CLL drugs Imbruvica (Johnson & Johnson) and Roche’s Gazyva.